In pancreatic cancer, SMYD2 was found to be overexpressed, and SMYD2 upregulated the MNAT1 component of CDK-activating kinase (MNAT1), which is a component of cyclin-dependent kinase (CDK)-activating kinase, via H3K36me2 modification in the promoter region. Here, SMYD2 is linked to familial pancreatic carcinoma.